Low Molecular Weight Protein Nephrotoxicity
Low Molecular Weight Protein Nephrotoxicity
批准号:
10578666
负责人:
PAUL W. SANDERS
金额:
$0.0万
依托单位国家:
美国
项目类别:
财政年份:
2015
资助国家:
美国
项目状态:
已结题
起止时间:
2015-07-01 至 2024-09-30
关键词:
AddressAffectAfrican AmericanAgingBindingCellsCellular biologyChronic Kidney FailureClinicalCreatinineCyclizationDevelopmentDiseaseDistalElementsEnvironmentEpidemiologyEpithelial CellsEpitheliumEpitopesEventExcisionExposure toGenerationsGlycoproteinsGoalsGrowth FactorHematologic NeoplasmsHigh PrevalenceHydrogen PeroxideHydrophobicityImmunoglobulinsIn VitroIncidenceIncubatedInflammatoryInjury to KidneyInterleukinsKidneyKidney DiseasesKidney FailureKnowledgeLaboratoriesLesionLightLight Chain Deposition DiseaseLinkMalignant - descriptorMalignant NeoplasmsMediatingModernizationMolecular WeightMonoclonal gammopathy of uncertain significanceMultiple MyelomaNephronsOxidation-ReductionOxidative StressPathogenesisPatientsPeptide HydrolasesPeptidesPlasma CellsPlayPredispositionProductionPrognosisPrognostic FactorProteinsProteolysisReactionRecovery of FunctionRenal Replacement TherapyRenal functionResistanceRodent ModelRoleSTAT1 proteinSeriesSerumSignal TransductionSiteStructureTherapeuticTimeTransforming Growth Factor betaTryptophanTubular formationUMOD geneVeteransWorkagent orangechemotherapyclinical practiceclinically relevantcomplementarity-determining region 3experimental studyimproved outcomein vivoin vivo Modelkidney dysfunctionkidney fibrosismilitary veterannephrotoxicitynovelnovel strategiespremalignantresponsetherapy design
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Multiple myeloma (MM) is a malignant plasma cell disorder that has an incidence rate of
about 1.1% among all malignancies and constitutes 12-13% of hematologic malignancies in the
US. The epidemiology is similar in our veteran population and includes a 3-fold higher
prevalence of monoclonal gammopathy of undetermined significance, a premalignant lesion, in
African American veterans. Renal dysfunction, determined by serum creatinine elevation ≥ 1.3
mg/dl, is frequently (about 48%) associated with MM, and an increase in the serum creatinine
concentration beyond 2.0 mg/dl portends a poor prognosis. One large study concluded that
reversibility of renal function was a more important prognostic factor than response to
chemotherapy. Recent work has shown that monoclonal immunoglobulin free light chains (FLC)
produced in multiple myeloma are biologically active proteins that generate intracellular
oxidative stress in the proximal tubule and promote significant changes in epithelial cell biology.
The working hypothesis of this application is that the physicochemical structure of the variable
domain of the FLC determines the type and consequences of tubulointerstitial renal disease in
myeloma.
To address this hypothesis, two aims are proposed:
Aim 1. Determine if susceptibility of the CDR3 domain to proteolysis is a determinant of cast
nephropathy. FLC may serve as substrates for kidney proteases; cleavage of the CDR3
domain opens the loop structure, changing the secondary structure, which affects binding to
THP. Hypothesis: resistance of the CDR3 domain to protease cleavage is a critical
determinant of binding to THP and development of cast nephropathy.
Aim 2. Define the role of redox signaling in the development of progressive kidney disease in
cast nephropathy. Hypothesis: nephrotoxic monoclonal FLCs promote a pro-
inflammatory/fibrotic state that stimulates an AKI to CKD transition.
Aim 2.1 Determine the function of Signal Transducer and Activator of Transcription 1 (STAT1)
in FLC nephrotoxicity. Hypothesis: STAT1 activation in kidney epithelium produces
IL-1b and TGF-b and plays a critical role in the development of CKD following AKI
due to cast nephropathy.
Aim 2.2 Determine if the intrinsic ability of the FLC to generate hydrogen peroxide is involved
in the development of myeloma kidney. Hypothesis: the production of hydrogen
peroxide by FLCs is a critical element in the generation of progressive kidney injury.
The proposal will use in vitro and in vivo models to determine how monoclonal FLCs
generate pro-inflammatory and pro-fibrotic growth factors that induce tubulointerstitial renal
fibrosis. The long-term goal of this proposal is to shift clinical practice paradigms in the
management of progressive renal failure occurring in the setting of MM, by exploring novel
theoretical concepts to devise strategies that limit the development of chronic kidney disease
and thereby improve outcomes in MM.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Pre-Clinical Core
-
批准号:10746570
-
项目类别:
-
资助金额:$25.2万
-
财政年份:2023
-
负责人:PAUL W. SANDERS
-
依托单位:
Vascular Mechanisms of Hypertensive Nephropathy
-
批准号:10533780
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2022
-
负责人:PAUL W. SANDERS
-
依托单位:
Vascular Mechanisms of Hypertensive Nephropathy
-
批准号:10363532
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2022
-
负责人:PAUL W. SANDERS
-
依托单位:
Low Molecular Weight Protein Nephrotoxicity
-
批准号:10041695
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2015
-
负责人:PAUL W. SANDERS
-
依托单位:
Low Molecular Weight Protein Nephrotoxicity
-
批准号:10295150
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2015
-
负责人:PAUL W. SANDERS
-
依托单位:
Low Molecular Weight Protein Nephrotoxicity
-
批准号:9778058
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2015
-
负责人:PAUL W. SANDERS
-
依托单位:
Low Molecular Weight Protein Nephrotoxicity
-
批准号:8277784
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2011
-
负责人:PAUL W. SANDERS
-
依托单位:
Low Molecular Weight Protein Nephrotoxicity
-
批准号:8696837
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2011
-
负责人:PAUL W. SANDERS
-
依托单位:
Low Molecular Weight Protein Nephrotoxicity
-
批准号:8140851
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2011
-
负责人:PAUL W. SANDERS
-
依托单位:
Low Molecular Weight Protein Nephrotoxicity
-
批准号:8398973
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2011
-
负责人:PAUL W. SANDERS
-
依托单位:
Mechanisms of Salt-Sensitive Hypertension and Hypertensive Nephrosclerosis
-
批准号:7903735
-
项目类别:
-
资助金额:$4.84万
-
财政年份:2009
-
负责人:PAUL W. SANDERS
-
依托单位:
Core B - Resource for Pre-Clinical Studies of AKI
-
批准号:10252038
-
项目类别:
-
资助金额:$25.44万
-
财政年份:2008
-
负责人:PAUL W. SANDERS
-
依托单位:
Pilot and Feasibility Program
-
批准号:10456261
-
项目类别:
-
资助金额:$15.03万
-
财政年份:2008
-
负责人:PAUL W. SANDERS
-
依托单位:
Pilot and Feasibility Program
-
批准号:10252040
-
项目类别:
-
资助金额:$15.03万
-
财政年份:2008
-
负责人:PAUL W. SANDERS
-
依托单位:
Core B - Resource for Pre-Clinical Studies of AKI
-
批准号:10456259
-
项目类别:
-
资助金额:$25.44万
-
财政年份:2008
-
负责人:PAUL W. SANDERS
-
依托单位:
Resource for Pre-Clinical Studies of AKI (Animal Models/lmaging/Renal Physiology
-
批准号:8733666
-
项目类别:
-
资助金额:$23.07万
-
财政年份:2008
-
负责人:PAUL W. SANDERS
-
依托单位:
Resource for Pre-Clinical Studies of AKI (Animal Models/lmaging/Renal Physiology
-
批准号:8625443
-
项目类别:
-
资助金额:$23.07万
-
财政年份:2008
-
负责人:PAUL W. SANDERS
-
依托单位:
Resource for Pre-Clinical Studies of AKI (Animal Models/lmaging/Renal Physiology
-
批准号:9124659
-
项目类别:
-
资助金额:$23.07万
-
财政年份:2008
-
负责人:PAUL W. SANDERS
-
依托单位:
Resource for Pre-Clinical Studies of AKI (Animal Models/lmaging/Renal Physiology
-
批准号:8899510
-
项目类别:
-
资助金额:$23.07万
-
财政年份:2008
-
负责人:PAUL W. SANDERS
-
依托单位:
NITRIC OXIDE AND HEREDITARY LOW RENIN HYPERTENSION
-
批准号:2145379
-
项目类别:
-
资助金额:$15.84万
-
财政年份:1992
-
负责人:PAUL W. SANDERS
-
依托单位:
海外基金